WO1996029045A1 - Compositions for the treatment of dandruff - Google Patents
Compositions for the treatment of dandruff Download PDFInfo
- Publication number
- WO1996029045A1 WO1996029045A1 PCT/US1996/003988 US9603988W WO9629045A1 WO 1996029045 A1 WO1996029045 A1 WO 1996029045A1 US 9603988 W US9603988 W US 9603988W WO 9629045 A1 WO9629045 A1 WO 9629045A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agent
- treatment
- dandruff
- composition
- antifungal agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
- A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4933—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having sulfur as an exocyclic substituent, e.g. pyridinethione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
Definitions
- the invention relates to pharmaceutical compositions for use in the treatment of seborrheic dermatitis of the scalp.
- Dandruff seborrheic dermatitis of the scalp, is a common disease involving 3-5% of the population. Dandruff is, in many cases, the precursor of alopecia (baldness) and constitutes a chronic and almost intractable cosmetical and social inconvenience. The pathophysiology of the disease remains unknown, although it is known to involve a hyperproliferat ⁇ ive state of the skin, a limited inflammatory process, and a secondary microbial colonization by the lipophilic yeast Pityrosporum, which is abundant and significantly ovcrpopulated on the scalp of seborrheic patients. Dandruff is a chronic and almost incurable disease. Available treatments result only in short term effects with an eventual recurrence of the disease.
- a traditional treatment of dandruff included administration onto the scalp of either a cytotoxic agent or an antifungal agent.
- a traditional treatment of dandruff included administration onto the scalp of either a cytotoxic agent or an antifungal agent.
- the present invention provides by a first of its aspects a composition, e g in the form of a hair shampoo, for the treatment of dandruff or of symptoms associated therewith, comprising in combination an effective amount of at least one cytotoxic agent and an effective amount of at least one antifungal agent, together with a carrier, a diluent or an excipient
- effective amount means to denote an amount of an agent effective in achieving a therapeutic result in the treatment of dandruff, such as alleviation of itching, a decrease in the amount of scales, a reduction in the rate of hair loss, a reduction in scalp redness, etc.
- cytotoxic agent as used herein means to denote an agent which inhibits proliferation of keratinocytes skin cells.
- antifungal agent will be used to denote an agent which is specifically active in inhibiting growth of fungus and the fungus' ability to colonize the skin, which includes, inter alia, agents which are destructive to fungi, or active in suppressing growth of fungus or affect their ability to reproduce
- cytotoxic agent refers to agents which arc known in the art primarily by having cytotoxic activity
- antifungal agent refers to agents which are known in the art primarily by their antifungal activity
- cytotoxic agents useful in accordance with the invention are coal tars, selenium sulfide, zinc pyrithione or the like.
- the preferred cytoxic agent is coal tar, typically included in the composition in concentration of 1-5%.
- antifungal agents useful in accordance with the invention include imidazoles, ciclopiroxolamines and metronidazolcs.
- the imidazoles which arc preferred in accordance with the invention, include ketoconozole, bifonazole, itraconazolc, cconazole, clotrimazole, miconazole, oxiconazole, isoconazolc and the like. From the imidazoles, ketoconozole is particularly preferred.
- the antifungal agent is included in the composition in a concentration of 0.5-5%
- the present invention further provides the use of said cytotoxic agent in combination with said antifungal agent for the preparation of a composition, e.g. a medical hair shampoo, for the treatment of dandruff.
- a composition e.g. a medical hair shampoo
- a further aspect of the invention is concerned with the treatment of individuals suffering from dandruff by combined application to the scalp of such individuals of said cytotoxic agent and of said antifungal agent.
- the individuals may be treated by the use of a single composition, e.g. in the form of a hair shampoo, comprising both agents.
- the individuals may be treated by a combination of two different compositions, one comprising said cytotoxic agent and the other said antifungal agent. The above described combination may be applied 3-4 times during the first week from the start of the treatment, and 1-2 times a week, thereafter.
- the present invention also pertains to a package comprising at least two compositions, one comprising said antifungal agent and the other said cytotoxic agent, optionally with instructions for use in said method.
- Example 1 A group of six patients (ages 17-38) with a severe case of dandruff were on a regular bi-weekly anti seborrheic treatment prior to the onset of the experiment. During the experiment they were treated with a combination of the following two compositions: a. a composition comprising 1.8% coal tar. b. a solution comprising 2% kctoconazole.
- the patients were instructed to apply the two compositions, one after the other, in an amount sufficient to cover the entire scalp.
- the patients were instructed to apply the compositions on days 1 , 3, 6 and 9.
- the patients' conditions were examined after 14 or 30 days following the onset of treatment.
- the patients' conditions were evaluated by the following criteria: (i) scaling - existence of scales on the scalp, typically at the temporal area; (ii) itching - based on the patient's subjective feeling; (iii) severity - overall assessment of the dandruff disease situation, taking into account the skin redness as an indication of inflammatorv conditions. - D -
- Example 1 A group of three patients who had no record of treatment for dandruff prior to the onset of the experiment, was given the same treatment as in Example 1. The patients' condition was as severe as in Example 1.
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/913,650 US6075017A (en) | 1995-03-21 | 1996-03-20 | Compositions for the treatment of dandruff |
AU55261/96A AU5526196A (en) | 1995-03-21 | 1996-03-20 | Compositions for the treatment of dandruff |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL113057 | 1995-03-21 | ||
IL11305795A IL113057A (en) | 1995-03-21 | 1995-03-21 | Compositions for the treatment of dandruff |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996029045A1 true WO1996029045A1 (en) | 1996-09-26 |
Family
ID=11067236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/003988 WO1996029045A1 (en) | 1995-03-21 | 1996-03-20 | Compositions for the treatment of dandruff |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU5526196A (en) |
IL (1) | IL113057A (en) |
WO (1) | WO1996029045A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997029733A1 (en) * | 1996-02-16 | 1997-08-21 | Janssen Pharmaceutica N.V. | Compositions containing an antifungal and a sulfur compound |
WO1999030675A1 (en) * | 1997-12-18 | 1999-06-24 | Johnson & Johnson Consumer Companies, Inc. | Methods for improving the health of hair and scalp |
WO2000006144A1 (en) * | 1998-07-27 | 2000-02-10 | Howard Murad | Pharmaceutical compositions and methods for managing scalp conditions |
DE19938404A1 (en) * | 1999-08-13 | 2001-02-22 | Clariant Gmbh | Cosmetic preparations |
US6469033B1 (en) | 1996-09-27 | 2002-10-22 | Aventis Pharma Deutschland Gmbh | Use of 1-hydroxy-2-pyridones for the treatment of skin diseases |
US6916479B2 (en) | 1997-04-14 | 2005-07-12 | Janssen Pharmaceutica N.V. | Compositions containing an antifungal and a phospholipid |
US7018656B2 (en) | 1996-09-27 | 2006-03-28 | Aventis Pharma Deutschland Gmbh | Antimycotic gel with high active substance release |
US7981909B2 (en) | 1996-09-27 | 2011-07-19 | Medicis Pharmaceutical Corporation | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4294852A (en) * | 1973-11-01 | 1981-10-13 | Johnson & Johnson | Skin treating compositions |
US4491588A (en) * | 1982-03-31 | 1985-01-01 | University Of Tennessee Research Corporation | Treatment of psoriasis and seborrheic dermatitis with imidazole antibiotics |
US4518789A (en) * | 1982-06-30 | 1985-05-21 | Yu Ruey J | Phenyl alpha-acyloxyacetamide derivatives and their therapeutic use |
-
1995
- 1995-03-21 IL IL11305795A patent/IL113057A/en not_active IP Right Cessation
-
1996
- 1996-03-20 WO PCT/US1996/003988 patent/WO1996029045A1/en active Application Filing
- 1996-03-20 AU AU55261/96A patent/AU5526196A/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4294852A (en) * | 1973-11-01 | 1981-10-13 | Johnson & Johnson | Skin treating compositions |
US4491588A (en) * | 1982-03-31 | 1985-01-01 | University Of Tennessee Research Corporation | Treatment of psoriasis and seborrheic dermatitis with imidazole antibiotics |
US4518789A (en) * | 1982-06-30 | 1985-05-21 | Yu Ruey J | Phenyl alpha-acyloxyacetamide derivatives and their therapeutic use |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997029733A1 (en) * | 1996-02-16 | 1997-08-21 | Janssen Pharmaceutica N.V. | Compositions containing an antifungal and a sulfur compound |
US6469033B1 (en) | 1996-09-27 | 2002-10-22 | Aventis Pharma Deutschland Gmbh | Use of 1-hydroxy-2-pyridones for the treatment of skin diseases |
US7018656B2 (en) | 1996-09-27 | 2006-03-28 | Aventis Pharma Deutschland Gmbh | Antimycotic gel with high active substance release |
US7026337B2 (en) | 1996-09-27 | 2006-04-11 | Aventis Pharma Deutschland Gmbh | Antimycotic gel having high active compound release |
US7981909B2 (en) | 1996-09-27 | 2011-07-19 | Medicis Pharmaceutical Corporation | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis |
US6916479B2 (en) | 1997-04-14 | 2005-07-12 | Janssen Pharmaceutica N.V. | Compositions containing an antifungal and a phospholipid |
WO1999030675A1 (en) * | 1997-12-18 | 1999-06-24 | Johnson & Johnson Consumer Companies, Inc. | Methods for improving the health of hair and scalp |
US6099870A (en) * | 1997-12-18 | 2000-08-08 | Johnson & Johnson Consumer Companies, Inc. | Methods for improving the health of hair and scalp |
WO2000006144A1 (en) * | 1998-07-27 | 2000-02-10 | Howard Murad | Pharmaceutical compositions and methods for managing scalp conditions |
DE19938404A1 (en) * | 1999-08-13 | 2001-02-22 | Clariant Gmbh | Cosmetic preparations |
WO2001012140A1 (en) * | 1999-08-13 | 2001-02-22 | Clariant Gmbh | Cosmetic preparations |
US6663875B2 (en) | 1999-08-13 | 2003-12-16 | Clariant Gmbh | Hair preparation for the treatment of dandruff |
Also Published As
Publication number | Publication date |
---|---|
AU5526196A (en) | 1996-10-08 |
IL113057A (en) | 1999-01-26 |
IL113057A0 (en) | 1995-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Faergemann | Management of seborrheic dermatitis and pityriasis versicolor | |
Healy et al. | PUVA treatment for alopecia areata—does it work? A retrospective review of 102 cases | |
EP0500745B1 (en) | Metal-peptide compositions and cosmetic methods for stimulating hair growth | |
EP0961609B1 (en) | Methods for improving the health of hair and scalp | |
EP0673643B1 (en) | Cosmetic composition containing an association of superoxide dismutase and porphyrine | |
EP0770376B1 (en) | Use of a substance P antagonist in a topical composition as antiperspirant | |
WO1996029045A1 (en) | Compositions for the treatment of dandruff | |
US6673842B2 (en) | Method of treating onychomycosis | |
US6075017A (en) | Compositions for the treatment of dandruff | |
DE3619904A1 (en) | AGENT TO BE ORALED | |
US20030181526A1 (en) | Method of treating onychomycosis | |
WO1999044579A2 (en) | Use of a compound inhibiting the activity of a sodium channel and a calcium channel in a composition for topical use | |
Ive | An overview of experience with ketoconazole shampoo | |
FR2769838A1 (en) | Use of azole derivatives to treat inflammation and sensitive skins | |
Golf et al. | Systemic short-term fibrinolysis with high-dose streptokinase in acute myocardial infarction: time course of biochemical parameters | |
EP1014928A2 (en) | Use of a serotonin antagonist or agonist respectively specific of the 5ht 2? and 5ht 1d? receptor in a cosmetic or dermatological composition for sensitive skin and resulting composition | |
JPH0112725B2 (en) | ||
WO2023217936A1 (en) | Novel use of a blend of sugars comprising psicose, mannose, fructose and glucose | |
McGavack et al. | A clinical investigation of beta-morpholino-ethyl benzhydryl ether hydrochloride (linadryl) as an antihistamine agent | |
Simpson et al. | The clinical evaluation of a new butyrophenone (WY-3457) | |
KR20220071218A (en) | Combination of ciclopiroxolamine and piroctone olamine to combat dandruff | |
EP4011360A1 (en) | Cosmetic complex for moisturizing skin, use of the cosmetic complex, cosmetic composition and skin moisturizing method | |
KR20090039458A (en) | A composition using the hair containing chamaecyparis obtusa oil | |
DE3340878C2 (en) | Orally applicable composition | |
AU2006203095A1 (en) | Methods for improving the health of hair and scalp |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 08913650 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |